cell-science-pharmacology-2017-scientifictracks

Page 21

Notes:

allied

academies

Cell Science, Stem Cell Research &

Pharmacological Regenerative Medicine

November 29-30, 2017 | Atlanta, USA

Annual Congress on

Adv cel sci tissue cul 2017 | Volume 1 Issue 2

Lung cancer and liquid biopsy

Nefize Sertac Kip

Icahn School of Medicine at Mount Sinai, USA

reatest advances have recently been made in genetics

to increase our understanding of the genetic basis of

human cancers. Many familial and somatic cancer genes with

high-penetrance mutations have already been identified,

but the situation is more complex for the contribution of

the low-penetrance variants. Circulating tumor DNA (ctDNA)

and cell-free DNA (cfDNA) have been shown to be elevated

in the plasma and urine of patients with malignancy, offering

clinical utility based on a blood draw and/or urine collection,

in multiple solid tumors to improve our understanding of

low-allelic fraction somatic variants. Multiple tumor type–

specific next-generation sequencing assays are currently

available which enable detection of somatic mutations in

plasma, down to an analytical sensitivity of 0.1% in clinically

relevant genes. This oral presentation will focus on the

recent advances achieved in the field of liquid biopsy, along

with our recent experience in Sema4 Laboratory, especially

in non-small cell lung cancer (NSCLC) specimens. Paired

plasma and/or urine samples with respective lung tissue

appear to ensure a deeper understanding of the molecular

pathogenesis of NSCLC, determine diagnosis and prognosis,

predict response to therapy, identify resistance variants,

assess minimal residual disease, characterize evolution of

the tumor, as well as shed light onto signaling networks that

orchestrate tumor behavior in a longitudinal manner, to

ultimately result in superior patient care.

Speaker Biography

Nefize Sertac Kip is a Pathologist who has completed her training at Mayo Clinic,

Rochester MN five years ago. She has triple boarded for anatomic, clinical and

molecular genetics pathology. She is currently working as the Director of Oncology

at Sema4 Genomics Laboratory at CT, which is a spinoff company out of Mount Sinai,

New York.